In late 2022, the results of a groundbreaking stage three trial for a ‘miracle’ new Alzheimer’s drug lecanemab were hailed as ...

Scientists may have uncovered a new mechanism for treating Alzheimer's disease, offering hope to millions of patients worldwide. The discovery involves the activation of the brain's cellular clean-up ...

Leqembi, first FDA-approved Alzheimer's drug, faces EMA rejection, but shares could potentially surge soon. See why I rate ...

An Alzheimer’s treatment from idea to market can take up to 20 years. After a long hiatus, the U.S. Food and Drug ...

New research shows astrocytes can remove Alzheimer’s-related amyloid-beta via autophagy, offering a promising new direction ...

Alzheimer's disease may damage the brain in two distinct phases, based on new research using sophisticated brain mapping ...

Roche drops a third Alzheimer’s candidate this year, terminating a partnership with UCB just four years after agreeing to ...

Rensselaer Polytechnic Institute (RPI) has been awarded two grants by the National Institute on Aging (NIA) to train graduate ...

Posterial Cortical Atrophy, sometimes called Benson’s disease, is a rare degenerative brain condition that affects the back ...

New details have emerged into how Alzheimer’s disease affects the brain. Researchers have identified cellular changes in the ...

An analysis of the genetic activity of brain cells in individuals who have died with Alzheimer's disease has revealed the ...

Neurophet has specialized in developing solutions for diagnosis support, treatment guides, and treatment devices targeting ...